1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Obesity - Drugs In Development, 2022, provides an overview of the Obesity (Metabolic Disorders) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Obesity is defined as having an excessive amount of body fat. Obesity increases risk of diseases and health problems such as heart disease, diabetes and high blood pressure. The predisposing factors include age, family history, quitting smoking, lack of sleep and certain medications. Treatment includes healthy lifestyle, medications and surgery.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Obesity - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Obesity (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Obesity (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Obesity and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 1, 10, 33, 62, 1, 2, 169, 69 and 2 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 52 and 14 molecules, respectively.
Obesity (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Obesity (Metabolic Disorders).
- The pipeline guide reviews pipeline therapeutics for Obesity (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Obesity (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Obesity (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Obesity (Metabolic Disorders)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Obesity (Metabolic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Obesity (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Obesity - Overview
- Obesity - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Obesity - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Obesity - Companies Involved in Therapeutics Development
- Obesity - Drug Profiles
- Obesity - Dormant Projects
- Obesity - Discontinued Products
- Obesity - Product Development Milestones
- Featured News & Press Releases
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
- Number of Products under Development for Rubella (German Measles), 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Products under Development by Companies, 2022
- Products under Development by Universities/Institutes, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Rubella (German Measles) - Pipeline by Amogen Pharma Pvt Ltd, 2022
- Rubella (German Measles) - Pipeline by Beijing Minhai Biotechnology Co Ltd, 2022
- Rubella (German Measles) - Pipeline by Daiichi Sankyo Co Ltd, 2022
- Rubella (German Measles) - Pipeline by Enesi Pharma Ltd, 2022
- Rubella (German Measles) - Pipeline by Indian Immunologicals Ltd, 2022
- Rubella (German Measles) - Pipeline by Micron Biomedical Inc, 2022
- Rubella (German Measles) - Pipeline by Sinovac Biotech Ltd, 2022
- Rubella (German Measles) - Pipeline by Vaxxas Inc, 2022
- Rubella (German Measles) - Pipeline by Zhongyianke Biotech Co Ltd, 2022
- Rubella (German Measles) - Pipeline by Zydus Lifesciences Ltd, 2022
- Rubella (German Measles) - Dormant Projects, 2022
- Number of Products under Development for Rubella (German Measles), 2022
- Number of Products under Development by Companies, 2022
- Number of Products by Top 10 Routes of Administration, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- 180 Life Sciences Corp
- 9 Meters Biopharma Inc
- Aardvark Therapeutics Inc
- Adare Pharma Solutions
- Adipo Therapeutics LLC
- Adocia SAS
- Agentix Corp
- AgeX Therapeutics Inc
- Altamira Therapeutics Ltd
- Altimmune Inc
- Amgen Inc
- Amogen Pharma Pvt Ltd
- Anagenesis Biotechnologies SAS
- Antag Therapeutics ApS
- AntiCancer Inc
- Aoxing Pharmaceutical Company Inc
- Aphaia Pharma AG
- Applied Molecular Transport Inc
- AptamiR Therapeutics Inc
- Aptorum Group Ltd
- AstraZeneca Plc
- August Therapeutics Inc
- AULBIO Co Ltd
- Autotac Bio Inc
- Betagenon AB
- BioRestorative Therapies Inc
- Biozeus Pharmaceutical SA
- Boehringer Ingelheim International GmbH
- Braasch Biotech LLC
- Bristol-Myers Squibb Co
- Bullfrog AI Inc
- Caliway Biopharmaceutics Co Ltd
- Callitas Therapeutics Inc
- Can-Fite BioPharma Ltd
- Caregen Co Ltd
- Carmot Therapeutics Inc
- Cellivery Therapeutics Inc
- Celloram Inc
- Centeer BioTherapeutics Ltd Co
- CinFina Pharma LLC
- Circadian Therapeutics
- CK Regeon Inc
- Clayton Biotechnologies Inc
- CohBar Inc
- Corbus Pharmaceuticals Inc
- Corcept Therapeutics Inc
- Courage Therapeutics Inc
- CURx Pharmaceuticals Inc
- CVI Pharmaceuticals US Inc
- Cyta Therapeutics Inc
- D&D Pharmatech Co Ltd
- Daewoong Pharmaceutical Co Ltd
- Dale Biotech LLC
- DD Therapeutics LLC
- DiscoveryBiomed Inc
- Dompe Farmaceutici SpA
- Dongkook Pharmaceutical Co Ltd
- Eccogene (Shanghai) Co Ltd
- Efil Bioscience Inc
- Elevian Inc
- Eli Lilly and Co
- Empros Pharma AB
- EncuraGen Co Ltd
- Energesis Pharmaceuticals Inc
- Enspire Bio Inc
- Enterin Inc
- Enterobiome
- Eolo Pharma
- ePurines Inc
- EraCal Therapeutics AG
- ERX Pharmaceuticals Inc
- Eternygen GmbH
- FGH BioTech Inc
- Gan & Lee Pharmaceuticals Co Ltd
- Genexine Inc
- Gila Therapeutics Inc
- Glaceum Inc
- Glucox Biotech AB
- Gmax Biopharm LLC
- GPER G-1 Development Group LLC
- Guangzhou BeBetter Medicine Technology Co Ltd
- Guangzhou Dazhou Biomedical Technology Co Ltd
- Gubra ApS
- Gusto Global LLC
- HanAll Biopharma Co Ltd
- Hangzhou Adamerck Pharmlabs Inc
- Hangzhou Jiuyuan Gene Engineering Co Ltd
- Hanmi Pharmaceuticals Co Ltd
- HEC Pharma Co Ltd
- Huadong Medicine Co Ltd
- i2O Therapeutics Inc
- Ildong Pharmaceutical Co Ltd
- Immungenetics AG
- ImmunoBiome Inc
- Infusion Biosciences
- Innovimmune Biotherapeutics Inc
- Intarcia Therapeutics Inc
- Inversago Pharma Inc
- Japan Tobacco Inc
- JD Bioscience Inc
- Jenrin Discovery Inc
- Jiangsu Hansoh Pharmaceutical Group Co Ltd
- Jiangsu Sinopep Allsino Biopharmaceutical Co Ltd
- Johnson & Johnson
- Kallyope Inc
- Kissei Pharmaceutical Co Ltd
- KSbitugen Co Ltd
- Kwang Dong Pharmaceutical Co Ltd
- Landsteiner Genmed SL
- Lead Discovery Center GmbH
- LG Chem Ltd
- Life Biosciences LLC
- Lipidio Pharmaceuticals Inc
- Lixte Biotechnology Holdings Inc
- MAKScientific LLC
- MD Healthcare Inc
- MeiraGTx Holdings Plc
- Merck & Co Inc
- Moon (Guangzhou) Biological Technology Co Ltd
- MThera Pharma Co Ltd
- Nano Intelligent Biomedical Engineering Corp
- NeonMind Biosciences Inc
- NeuroNano Pharma Inc
- NGM Biopharmaceuticals Inc
- NIMIUM Therapeutics Inc
- Nordic Bioscience AS
- Novartis AG
- NovMetaPharma Co Ltd
- Novo Nordisk AS
- Nubiyota LLC
- NuSirt Biopharma Inc
- ObeTherapy Biotechnology
- Ochre Bio Ltd
- Omeros Corp
- OPKO Health Inc
- Oramed Pharmaceuticals Inc
- Orbit Discovery Ltd
- Otsuka Pharmaceutical Co Ltd
- Oxt Therapeutics Inc
- Palatin Technologies Inc
- PegBio Co Ltd
- Pfizer Inc
- PhageNova Bio Inc
- Preveceutical Medical Inc
- Primetime Life Sciences LLC
- Protheragen Inc
- Pylum Biosciences Inc
- Qoracle Co Ltd
- Ramino-Bio Ltd
- Raziel Therapeutics
- Regeneron Pharmaceuticals Inc
- Remd Biotherapeutics Inc
- Renova Therapeutics Inc
- Repurpose.AI Inc
- Resalis Therapeutics Srl
- Reviva Pharmaceuticals Inc
- Rhamnopharma Inc
- Rhythm Pharmaceuticals Inc
- Rivus Pharmaceuticals Inc
- RosVivo Therapeutics Inc
- Saniona AB
- Sanofi
- Scioto Biosciences Inc
- Sciwind Biosciences Co Ltd
- Scohia Pharma Inc
- Senda Biosciences Inc
- Shanghai Benemae Pharmaceutical Corp
- Shanghai Fosun Pharmaceutical (Group) Co Ltd
- Shanghai Innogen Pharmaceutical Technology Co Ltd
- Shenzhen Salubris Pharmaceuticals Co Ltd
- Shionogi & Co Ltd
- Sigrid Therapeutics AB
- Siragen Pharmaceuticals Inc
- Sirnaomics Ltd
- SJT Molecular Research SL
- SK Bioscience Ltd
- Slate Bio Inc
- Soleno Therapeutics Inc
- Structure Therapeutics Inc
- Sun Pharmaceutical Industries Ltd
- Takeda Pharmaceutical Co Ltd
- Techfields Pharma Co Ltd
- Terns Pharmaceuticals Inc
- The United Laboratories International Holdings Ltd
- Trigemina Inc
- Tryp Therapeutics Inc
- Twinpigbiolab Co Ltd
- Twist Bioscience Corp
- UGISense AG
- Uni-Bio Science Group Ltd
- Versanis Bio Inc
- Viking Therapeutics Inc
- Virtici LLC
- Vivus LLC
- XL-protein GmbH
- Youngene Therapeutics Co Ltd
- YSOPIA Bioscience SA
- Yuhan Corp
- Zealand Pharma AS
- Zhejiang Doer Biologics Corp
- Zihipp Ltd
- Zylem Biosciences Inc
